There are scarce data on risk factors for postinfectious irritable bowel syndrome (PIIBS). The objective of this study was to determine the risk factors of developing PIIBS following an acute infectious gastroenteritis (AGE) episode in which, by laboratory tests, the etiological
agent was isolated. The study was conducted on patients admitted to a tertiary center of infectious diseases during three consecutive years. The patients were divided into two groups: a group consisting of patients admitted with AGE (with an isolated etiological agent) and a control
group consisting of patients admitted for an acute upper respiratory tract infection (URTI). The subjects were recalled in our center 6 months after the admission and were evaluated with Rome III IBS diagnostic questionnaire and Bristol Stool Form Scale. The questionnaires were
paper printed and directly filled in by the subjects. The response rate in the case group was 5% and in the control group 100%. The prevalence of PIIBS was higher in patients with AGE, presenting a relative risk (RR) of 4.16 [95% confidence interval (CI), 1.899.17],
statistically significant (P<0.001) vs. URTI. From 28 female patients, 22 patients (79%) developed PIIBS and from 17 male patients, 3 patients (18%) had developed PIIBS with a risk of 4.4 (95% CI, 1.5612.65), P<0.001. Regarding the infectious etiology
of the AGE, Campylobacter jejuni had the highest risk of developing PIIBS, RR=1.2 (95% CI, 0.133.11), P=0.04 compared with the other agents with a lower risk. The risk to develop PIIBS after AGE infection is 4.16 higher than after URTI. Female sex is a risk factor for PIIBS,
79% of the female patients developed PIIBS after AGE. The incidence of PIIBS is highest in patients with Campylobacter jejuni AGE compared with the other agents.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Infectious Diseases, ‘Iuliu Haieganu’ University of Medicine and Pharmacy, 400348 ClujNapoca, Romania
Second Medical Department, ‘Iuliu Haieganu’ University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites